Pediatric Hematology and Oncology Research | LifeBridge Health

Why is Clinical Research Crucial

Clinical research is the driving force behind the development of new and safe drugs, surgical procedures, devices and other therapies designed to address a wide variety of health conditions faced by patients with cancer and hematological diseases.

The Division of Pediatric Hematology/Oncology and the Herman & Walter Samuelson Children’s Hospital at Sinai is committed to providing patients with the opportunity to participate in clinical trials. By joining a research trial, patients gain access to innovative treatments or interventions while also contributing to the advancement of medical science.

The Division of Pediatric Hematology/Oncology and the Herman & Walter Samuelson Children’s Hospital at Sinai are located within Sinai Hospital of Baltimore, the largest community hospital in Maryland.

Doctor speaking with a young cancer patient

What sets us apart

As members in good standing of the Children’s Oncology Group, a National Cancer Institute (NCI) sponsored clinical trials cooperative, our dedicated team of clinical investigators provide up-to-date treatments through research collaborations with national and international experts. Additionally, we are proud members of the American Society of Hematology, further demonstrating our commitment to excellence in the field.

Our compassionate and knowledgeable team understands the unique needs of patients and their families. We are committed to providing the information and resources you need to make an informed decision about participating in a research trial. We will take the time to answer your questions, address your concerns, and ensure that you have a clear understanding of what to expect throughout the enrollment process and thereafter.

Who We Are

Important points of contact for anyone wishing to become part of a pediatric research trial:

Bilguis Al-Eryani, MBBS, MIH, CCRP

Research Program Manager

410-601-9882

Ana Cahuas, BS, MT (ASCP)

Research Coordinator

410-601-6708

Hematology/Oncology Attendings

Aziza Shad, MD

Jason Fixler, MD

Yoram Unguru, MD, MS, MA

Jennie Hart, MD

Yevgeniya Bamme, MD

Learn more about our attendings

Active Clinical Trials

Below is a list of active LifeBridge Health pediatric hematology and oncology research trials.
Click the dropdown menu to filter by specific types of cancer research.

Pediatric Acute Leukemia (PedAL) Screening Trial – Developing New Therapies for Relapsed Leukemias

Study # APAL2020SC Date Opened: 04/18/2022

A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-risk and Low-risk Fusion Negative Rhabdomyosarcoma

Study # ARST2032 Date Opened: 08/04/2022

A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) plus VINO-CPO Maintenance i

Study # ARST2031 Date Opened: 09/14/2021

Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)

Study # AREN1921 Date Opened: 10/19/2020

A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# 141913) in Children with Relapsed, Refractory or Progressive Neuroblastoma

Study # ANBL1821 Date Opened: 07/08/2019

A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)

Study # ANBL1531 Date Opened: 05/14/2018

Neuroblastoma Biology Studies

Study # ANBL00B1 Date Opened: 11/06/2000

Renal Tumors Classification, Biology, and Banking Study

Study # AREN03B2 Date Opened: 02/27/2006

A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma

Study # AOST2032 Date Opened: 03/03/2023

A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma

Study # AOST2031 Date Opened: 04/01/2022

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

Study # AALL1732 Date Opened: 10/31/2019

A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphobl

Study # AALL1731 Date Opened: 07/03/2019

International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones

Study # AALL1631 Date Opened: 08/08/2017

A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)

Study # AALL1621 Date Opened: 06/19/2017

Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)

Study # AAML18P1 Date Opened: 11/08/2019

Larotrectinib (LOXO-101, NSC# 788607, IND# 141824) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias

Study # ADVL1823 Date Opened: 10/25/2019

A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations AAML1831

Study # AAML1831 Date Opened: 07/21/2020

A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma

Study # E4412 Date Opened: 03/17/2014